Skip to content

Allogene Therapeutics, Inc.

ALLO

CIK 0001737287

← back to feed
Revenue (TTM)
$0
−100.0% YoY Q1 May 2026
Net Income (TTM)
−$194.68M
+25.9% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.88
+34.1% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$189.53M
Q1 May 2026
Cash
$30.31M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
345.15M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings